Cleared Traditional

K120051 - SODIUM CHLORIDE INHALATION SOLUTION, 3%, 7%, AND 10%, USP-4ML

K120051 is an FDA 510(k) clearance for SODIUM CHLORIDE INHALATION SOLUTION, manufactured by Nephron Pharmaceuticals Corp.. The device is a Class 2 Anesthesiology device with product code CAF cleared through the Traditional 510(k) pathway after a 105-day FDA review.

K120051 · Nephron Pharmaceuticals Corp. · Anesthesiology device
Download Printable Device Report (PDF) Official FDA 510(k) Summary (PDF)
Optimized for regulatory review, auditing and printing
Apr 2012
Decision
105d
Days
Class 2
Risk

K120051 is an FDA 510(k) clearance for the SODIUM CHLORIDE INHALATION SOLUTION, 3%, 7%, AND 10%, USP-4ML. Classified as Nebulizer (direct Patient Interface) (product code CAF), Class II - Special Controls.

Submitted by Nephron Pharmaceuticals Corp. (Orlando, US). The FDA issued a Cleared decision on April 20, 2012 after a review of 105 days - within the typical 510(k) review window.

This device falls under the Anesthesiology FDA review panel, regulated under 21 CFR 868.5630 - the FDA anesthesiology and respiratory device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Anesthesiology review framework, consistent with the majority of Class II 510(k) submissions.

FDA 510(k) Submission Details - K120051

510(k) Number K120051 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received January 06, 2012
Decision Date April 20, 2012
Days to Decision 105 days
Submission Type Traditional
Review Panel Anesthesiology (AN)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
35d faster than avg
Panel avg: 140d · This submission: 105d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

CAF Device Classification - Class 2, Special Controls

Product Code CAF Nebulizer (direct Patient Interface)
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 868.5630
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Anesthesiology devices follow this clearance model.

Regulatory Peers - CAF Nebulizer (direct Patient Interface)

All 441
Devices cleared under the same product code (CAF) and FDA review panel - the closest regulatory comparables to K120051.
SODIUM CHLORDE INHALATION SOLUTION, 0.9% USP-3ML
K113033 · Nephron Pharmaceuticals Corp. · Jun 2012
ERAPID NEBULIZER SYSTEM
K112859 · Pari Respiratory Equipment, Inc. · May 2012
AERONEB PRO
K120939 · Aerogen, Ltd. · Apr 2012
KOO SMALL VOLUME NEBULIZER (SVN)
K112041 · Koo (Shanghai) Industries Co., Ltd. · Dec 2011
QUIXIE NEBULIZER
K112564 · Odyssey Medical Technologies · Nov 2011
I-NEB AAD SYSTEM WITH TIM
K102454 · Respironics Respiratory Drug Delivery (Uk) , Ltd. · Oct 2011